Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications.
The skeletal and immune systems have a complex relationship. Both systems are intimately coupled, with osteoclastogenesis and hematopoiesis occurring in the bone marrow. Bone and immune cells also share common hematopoietic precursors. Furthermore, the skeletal and immune systems share various cytokines, receptors, and transcription factors that regulate signal transduction pathways involved in osteoclastogenesis and immune system activation, including the receptor activator of nuclear factor-κΒ ligand/receptor activator of nuclear factor-κΒ/osteoprotegerin (RANKL-RANK-OPG) pathway. Cancer cells can disrupt both the skeletal and immune systems. Interaction between cancer and bone cells results in a vicious cycle of bone destruction and cancer growth. Bone remodeling generates a growth-factor-rich environment that attracts cancer cells and promotes their proliferation. In turn, cancer cells stimulate osteoclast formation and activity, resulting in additional bone resorption that further stimulates cancer cell growth. Currently available bone-targeted therapies may also modulate the immune system. Bisphosphonates such as zoledronic acid exert stimulating effects on the immune system, resulting in possible anticancer activity against malignant cells. Denosumab, an anti-RANKL monoclonal antibody with proven antiosteoclast activity, may suppress immune responses. This may result in the reported association with an increased risk of neoplasms, as well as serious skin and other infections as reported in some studies, mainly in the postmenopausal setting. When assessing bone-targeted therapies, it is important to consider the shared signaling pathways between bone and the immune system, as well as the clinical risk:benefit ratio.
Department of Clinical Therapeutics, Alexandra General Hospital, University of Athens School of Medicine, 80 Vas. Sofias Avenue, 11528 Athens, Greece. eterpos@med.uoa.gr
Evangelos
E
Terpos
Meletios A
MA
Dimopoulos
D001847:Bone Diseases / Q000150:complications / Q000276:immunology / Q000503:physiopathology*; D006801:Humans; D007154:Immune System Diseases / Q000150:complications / Q000503:physiopathology*; D009369:Neoplasms / Q000209:etiology / Q000276:immunology / Q000503:physiopathology*; D015398:Signal Transduction
Ann Oncol. 2005 Aug;16(8):1223-31
15928069
Immunol Rev. 2005 Dec;208:88-105
16313343
Med Oncol. 2005;22(2):195-201
15965284
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6158-63
15073337
J Clin Invest. 2006 Nov;116(11):2869-79
17053833
J Leukoc Biol. 2010 Nov;88(5):877-84
20573802
Nature. 2006 Mar 30;440(7084):692-6
16572175
Ann Oncol. 2012 Sep;23(9):2271-2277
22383680
Dev Cell. 2002 Dec;3(6):889-901
12479813
Lancet. 1992 Oct 31;340(8827):1049-52
1357451
Mayo Clin Proc. 2003 Jan;78(1):21-33
12528874
Cell. 1997 Apr 18;89(2):309-19
9108485
J Clin Oncol. 2005 May 20;23(15):3314-21
15738536
J Exp Med. 2006 Nov 27;203(12):2673-82
17088434
Clin Exp Metastasis. 1992 Nov;10(6):403-10
1451350
Clin Exp Metastasis. 2003;20(7):639-46
14669795
Cancer Res. 2003 Sep 1;63(17):5438-45
14500379
Oncology. 2005;69(1):35-43
16088233
Nat Rev Immunol. 2007 Apr;7(4):292-304
17380158
Nat Rev Clin Oncol. 2009 Jun;6(6):339-51
19399023
J Clin Oncol. 2010 Dec 10;28(35):5132-9
21060033
J Clin Pathol. 2008 May;61(5):577-87
18441154
J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78
18695136
EMBO J. 2001 Mar 15;20(6):1271-80
11250893
Ther Clin Risk Manag. 2008 Apr;4(2):453-8
18728841
Am J Pathol. 2003 Nov;163(5):2021-31
14578201
Ann Rheum Dis. 2009 May;68(5):744-50
18480308
Lancet Oncol. 2009 Sep;10(9):872-6
19674936
Recent Results Cancer Res. 2003;162:79-87
12790323
Blood. 2000 Jul 15;96(2):384-92
10887096
Endocr Rev. 2008 Apr;29(2):155-92
18057140
J Clin Oncol. 2008 Oct 20;26(30):4875-82
18725648
Physiol Genomics. 2008 Sep 17;35(1):75-85
18612084
J Bone Miner Res. 2004 Feb;19(2):207-13
14969390
Br J Cancer. 2010 Mar 30;102(7):1099-105
20234364
Br J Haematol. 2001 Jun;113(4):1035-43
11442499
Autoimmun Rev. 2009 Jan;8(3):250-5
18722561
Blood. 2001 Dec 15;98(13):3527-33
11739153
N Engl J Med. 2009 Aug 20;361(8):756-65
19671655
J Clin Oncol. 2002 May 1;20(9):2353-9
11981007
Nature. 2002 Apr 18;416(6882):744-9
11961557
Immunol Rev. 2005 Dec;208:126-40
16313345
Trends Mol Med. 2008 Jun;14(6):245-53
18468489
Eur J Haematol. 2003 Jan;70(1):34-42
12631257
J Pathol. 2002 Oct;198(2):228-36
12237883
Cancer J. 2001 Sep-Oct;7(5):377-87
11693896
Expert Opin Investig Drugs. 2009 Aug;18(8):1085-102
19558335
Adv Exp Med Biol. 2010;658:11-20
19950011
Blood. 2002 Dec 15;100(13):4615-21
12393684
Int J Clin Oncol. 2010 Aug;15(4):382-9
20354750
Cancer Immunol Immunother. 2009 Jan;58(1):31-8
18458903
J Biol Chem. 2005 Sep 23;280(38):32905-13
16046394
Indian J Clin Biochem. 2009 Jul;24(3):229-33
23105840
J Bone Miner Res. 1999 Feb;14(2):256-63
9933480
Lancet. 2010 Dec 11;376(9757):1989-99
21131037
Am J Pathol. 1986 Apr;123(1):39-45
3457536
Br J Haematol. 1994 Aug;87(4):725-9
7986713
Curr Opin Pharmacol. 2006 Jun;6(3):307-12
16650801
Nature. 2004 Apr 15;428(6984):758-63
15085135
N Engl J Med. 2009 Feb 12;360(7):679-91
19213681
J Biol Chem. 1998 Oct 23;273(43):28355-9
9774460
J Biol Chem. 1997 Oct 3;272(40):25190-4
9312132
Blood. 2003 Mar 15;101(6):2094-8
12424190
EMBO Rep. 2005 Feb;6(2):171-6
15678156
Science. 1979 Jan 12;203(4376):176-9
569363
Oncol Res. 2010;18(10):493-501
20681408
Urology. 2001 Apr;57(4):611-6
11306358
Nat Med. 2006 Dec;12(12):1410-6
17128269
Cancer Treat Rev. 2008;34 Suppl 1:S25-30
18486347
Gene. 2006 May 10;372:92-102
16513293
Int J Cancer. 2005 Jan 20;113(3):364-71
15455384
N Engl J Med. 1996 Feb 22;334(8):488-93
8559201
Blood. 2002 Oct 15;100(8):3002-7
12351414
J Urol. 2009 Aug;182(2):509-15; discussion 515-6
19524963
Endocrinology. 1999 Oct;140(10):4451-8
10499498
Lung Cancer. 2001 Dec;34 Suppl 3:S25-9
11740989
Int J Cancer. 2009 Oct 1;125(7):1705-9
19521984
Blood. 2001 May 1;97(9):2917-8
11345090
Nature. 2000 Nov 30;408(6812):600-5
11117749
Br J Haematol. 1998 Feb;100(2):317-25
9488619
Horm Metab Res. 2009 Oct;41(10):721-9
19536731
Clin Cancer Res. 2003 Jul;9(7):2587-97
12855635
Cancer. 2001 Apr 1;91(7):1191-200
11283917
J Clin Invest. 2000 Dec;106(12):1481-8
11120755
J Exp Med. 2005 Sep 5;202(5):589-95
16147974
J Biol Chem. 2004 Oct 29;279(44):45969-79
15304486
Dtsch Med Wochenschr. 2008 Feb;133(7):285-9
18253918
J Surg Res. 2001 Sep;100(1):18-24
11516200
Cancer. 2004 Jun 15;100(12):2613-21
15197804
Nature. 2010 Nov 4;468(7320):103-7
20881963
Biochem Biophys Res Commun. 2007 Jun 15;357(4):1046-52
17462597
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4482-6
17671133
Autoimmun Rev. 2008 May;7(5):370-5
18486924
J Natl Cancer Inst. 2004 Jun 2;96(11):879-82
15173273
Cancer. 2003 Oct 15;98(8):1735-44
14534891
Annu Rev Immunol. 2006;24:33-63
16551243
Cancer Treat Rev. 2008 Feb;34(1):92-101
17964729
Adv Immunol. 2007;95:149-65
17869613
Bone. 2007 Apr;40(4):981-90
17196895
J Exp Med. 2005 Nov 7;202(9):1261-9
16275763
Clin Exp Metastasis. 1992 Nov;10(6):411-8
1451351
J Clin Oncol. 2003 Aug 15;21(16):3150-7
12915606
J Clin Oncol. 1998 Feb;16(2):593-602
9469347
Br J Cancer. 2000 Apr;82(8):1459-68
10780527
Clin Cancer Res. 2009 Jan 15;15(2):677-83
19147774
EMBO J. 2005 Feb 23;24(4):790-9
15678102
Clin Dev Immunol. 2007;2007:75805
18320012
Blood. 2009 Apr 2;113(14):3139-46
19171876
Endocr Rev. 2008 Jun;29(4):403-40
18451259
N Engl J Med. 2009 Aug 20;361(8):745-55
19671656
Biochem Biophys Res Commun. 1997 May 8;234(1):137-42
9168977
Lancet Oncol. 2010 Mar;11(3):275-80
20149736
J Clin Oncol. 1993 Jan;11(1):59-65
8418243